News AHA: MSD's oral PCSK9 matches injectables MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill.
News MSD, Ionis trumpet lipid-lowering drug data MSD's enlicitide scores in hypercholesterolaemia, as Ionis lines up broader use for recent approval Tryngolza in severe hypertriglyceridaemia.
News Update: Rumour confirmed as Lilly buys Verve Therapeutics Ahead of an opt-in decision on a PCSK9 inhibitor candidate, Eli Lilly is reported to be in advanced takeover negotiations with Verve Therapeutics.
News MSD moves ahead in race to bring oral PCSK9 drug to market Armed with positive results in two phase 3 trials, MSD is poised to be the first to file for approval of an oral PCSK9 drug to lower cholesterol.
News Study links 'bad cholesterol' to dementia Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, and statins could add to the benefit, according to a just-published study.
News ACC25: AZ stakes its claim to the oral PCSK9 category AstraZeneca reveals phase 2b results with its oral PCSK9 inhibitor AZD0780 as it tries to narrow a lead held by MSD with its rival cholesterol drug.
News NHS staff 'feel unprepared for digital transformation' A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
